Metastatic Malignant Neoplasm

Oncology
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Tempus
TempusIL - Chicago
1 program
1
Targeted Therapy Based on Molecular ProfilingPhase 21 trial
Active Trials
NCT02152254Active Not RecruitingEst. Dec 2030
NextPoint Therapeutics
2 programs
2
NPX267Phase 11 trial
NPX887Phase 11 trial
Active Trials
NCT05958199Suspended131Est. Sep 2025
NCT06240728Recruiting144Est. Aug 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TempusTargeted Therapy Based on Molecular Profiling
NextPoint TherapeuticsNPX887
NextPoint TherapeuticsNPX267

Clinical Trials (3)

Total enrollment: 275 patients across 3 trials

NCT02152254TempusTargeted Therapy Based on Molecular Profiling

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

Start: May 2014Est. completion: Dec 2030
Phase 2Active Not Recruiting

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Start: Jan 2024Est. completion: Aug 2027144 patients
Phase 1Recruiting

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Start: Jul 2023Est. completion: Sep 2025131 patients
Phase 1Suspended

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 275 patients
2 companies competing in this space